Eli Lilly's orforglipron has surpassed Novo Nordisk's Rybelsus in multiple key performance metrics, delivering superior weight loss and A1C reductions, as reflected in recent study results. With Eli Lilly reporting $14.7 billion in sales for the first half of 2025, the company capitalizes on growing investor confidence, while Novo Nordisk faces a 28.1% year-to-date decline in shares and a negative sales outlook. As competition heats up in the multi-billion-dollar GLP-1 market, both companies are poised to face significant changes amid rising obesity treatment demands.
“VK2735 · achieved weight loss results similar to · Eli Lilly's drug · 12% body weight loss”
“GLP-1 market · has been in the spotlight for · the past couple of years · multi-billion-dollar potential”
“Novo Nordisk · currently dominates · GLP-1 market · true”
“Eli Lilly · currently dominates · GLP-1 market · true”
“Eli Lilly · reported · ACHIEVE-3 head-to-head study data · orforglipron outperformed Rybelsus”
“Novo Nordisk · responded with data from · REACH real-world head-to-head study · true”
“NVO’s Ozempic · reduced the risk of MACE · 23% compared with LLY’s Trulicity · true”
“Ozempic · remains the only GLP-1 RA approved to lower · risk of kidney disease progression and cardiovascular death · true”
“Novo Nordisk · secured · EU approval to add cardiovascular benefits to Rybelsus · true”
“Mounjaro and Zepbound · have become · LLY’s key top-line drivers · true”
“Eli Lilly · generated combined sales of · $14.7 billion in the first half of 2025 · true”
“LKTX · is developing · VK2735 · as an oral and subcutaneous formulations for obesity”
